Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-11-02
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate RASH PRURITIC — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-14 (study day 13.0); relationship: POSSIBLE
moderate
assessed
Moderate WOUND HAEMORRHAGE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-09 (study day 69.0); relationship: POSSIBLE
Data queries
No data queries.